
Revolution Medicines Shares Clinical Updates on RAS(ON) Inhibitor Portfolio
Revolution Medicines a clinical-stage oncology company developing targeted therapies for RAS-driven cancers, announced significant clinical updates from its RAS(ON) inhibitor portfolio. The data, presented during an investor webcast, focused on the Phase 1 RMC-6236 monotherapy study in pancreatic ductal adenocarcinoma…